{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:43:59Z","timestamp":1787161439116,"version":"build-2736575974"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00277-022-04943-3","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T04:03:52Z","timestamp":1660881832000},"page":"2559-2561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation"],"prefix":"10.1007","volume":"101","author":[{"given":"Jessica M.","family":"Stempel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"6","key":"4943_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1182\/blood.V82.6.1749.1749","volume":"82","author":"U Budde","year":"1993","unstructured":"Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM (1993) Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 82(6):1749\u20131757","journal-title":"Blood"},{"key":"4943_CR2","unstructured":"National Comprehensive Cancer Network. Myeloproliferative neoplasms (version 1.2022). Retrieved from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 21 Mar\u00a02022"},{"issue":"25","key":"4943_CR3","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","volume":"117","author":"A Tiede","year":"2011","unstructured":"Tiede A, Rand JH, Budde U, Ganser A, Federici AB (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777\u20136785. https:\/\/doi.org\/10.1182\/blood-2010-11-297580","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04943-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04943-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T01:03:05Z","timestamp":1665104585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04943-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":3,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4943"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04943-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual described in this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"A. M. Z. received research funding (institutional) from Celgene\/BMS, Abbvie, Astex, Pfizer, Medimmune\/AstraZeneca, Boehringer-Ingelheim, Trovagene\/Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A. M. Z. participated in advisory boards, and\/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene\/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, and Tyme. A. M. Z. served on clinical trial committees for Novartis, Abbvie, Geron, and Celgene\/BMS. A. M. Z. received travel support for meetings from Pfizer, Novartis, and Cardiff Oncology. N. A. P. received consulting fees from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene\/Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation Pharmaceuticals, and AbbVie; other financial support for serving on an Independent Data Review Committee for Cogent Biosciences. R. M. S. participated in advisory boards and\/or had a consultancy with and received honoraria from Bristol Myers Squibb and Gilead Sciences, Inc. All other authors have nothing to disclose. None of these relationships was related to the development of this work. Other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}